Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).
Tsuchida KI, Taneda S, Yokota I, Okada K, Kurihara Y, Yokoyama H, Iwamoto M, Yamazaki K, Ishigaki Y, Manda N, Maegawa H; Japan Diabetes Clinical Data Management Study Group (JDDM study group). Tsuchida KI, et al. Among authors: taneda s. J Diabetes Investig. 2022 Nov;13(11):1834-1841. doi: 10.1111/jdi.13877. Epub 2022 Jul 5. J Diabetes Investig. 2022. PMID: 35735780 Free PMC article.
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Kito K, Nomoto H, Sakuma I, Nakamura A, Cho KY, Kameda H, Miya A, Omori K, Yanagiya S, Handa T, Taneda S, Takeuchi J, Nagai S, Yamashita K, Kurihara Y, Atsumi T, Miyoshi H; PARM-T2D study group. Kito K, et al. Among authors: taneda s. Diabetes Res Clin Pract. 2022 Oct;192:110091. doi: 10.1016/j.diabres.2022.110091. Epub 2022 Sep 26. Diabetes Res Clin Pract. 2022. PMID: 36174777
Radioimmunoassay for nonenzymatically glycated protein in human serum.
Nakayama H, Taneda S, Manda N, Aoki S, Komori K, Kuroda Y, Misawa K, Tsushima S, Nakagawa S. Nakayama H, et al. Among authors: taneda s. Clin Chim Acta. 1986 Aug 15;158(3):293-9. doi: 10.1016/0009-8981(86)90294-9. Clin Chim Acta. 1986. PMID: 3095001 No abstract available.
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
Kamoshima H, Nomoto H, Yamashita K, Takahashi Y, Tsuchida K, Kuwabara S, Miya A, Cho KY, Kameda H, Nakamura A, Atsumi T, Taneda S, Kurihara Y, Aoki S, Ono Y, Miyoshi H. Kamoshima H, et al. Among authors: taneda s. Endocr J. 2022 May 30;69(5):495-509. doi: 10.1507/endocrj.EJ21-0573. Epub 2021 Nov 25. Endocr J. 2022. PMID: 34819409 Free article.
Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
Son C, Makino H, Kasahara M, Tanaka T, Nishimura K, Taneda S, Nishimura T, Kasama S, Ogawa Y, Miyamoto Y, Hosoda K. Son C, et al. Among authors: taneda s. Diabetes Res Clin Pract. 2021 Oct;180:109037. doi: 10.1016/j.diabres.2021.109037. Epub 2021 Sep 2. Diabetes Res Clin Pract. 2021. PMID: 34481910 Free article. Clinical Trial.
134 results